Literature DB >> 27914096

Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases.

Taku Fujimura1, Yumi Kambayashi1, Sadanori Furudate1, Takanori Hidaka1, Yota Sato1, Kayo Tanita1, Hisayuki Tono1, Akira Tsukada1, Akira Hashimoto1, Setsuya Aiba1.   

Abstract

Because the efficacy rates of monotherapy with immune checkpoint inhibitors such as nivolumab or ipilimumab are not sufficient, to enhance the antitumor effects of these reagents is of great interest among dermato-oncologists. In this report, we describe two cases of multiple in-transit metastatic melanomas on the leg successfully treated with intensity-modulated radiotherapy (IMRT) using a CyberKnife in combination with ipilimumab or nivolumab. Our cases suggested that IMRT could enhance the antitumor effects of immune checkpoint inhibitors in patients with multiple in-transit melanomas.
© 2016 Japanese Dermatological Association.

Entities:  

Keywords:  immune checkpoints inhibitors; in-transit melanoma; intensity-modulated radiotherapy; ipilimumab; nivolumab

Mesh:

Substances:

Year:  2016        PMID: 27914096     DOI: 10.1111/1346-8138.13707

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

Review 1.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

2.  Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod.

Authors:  Taku Fujimura; Yumi Kambayashi; Yota Sato; Kayo Tanita; Sadanori Furudate; Akira Tsukada; Hisayuki Tono; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-01-04

3.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13

4.  Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.

Authors:  Kayo Tanita; Taku Fujimura; Yumi Kambayashi; Akira Tsukada; Yota Sato; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-02-15

5.  Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.

Authors:  Taku Fujimura; Yota Sato; Kayo Tanita; Yumi Kambayashi; Atsushi Otsuka; Yasuhiro Fujisawa; Koji Yoshino; Shigeto Matsushita; Takeru Funakoshi; Hiroo Hata; Yuki Yamamoto; Hiroshi Uchi; Yumi Nonomura; Ryota Tanaka; Megumi Aoki; Keisuke Imafuku; Hisako Okuhira; Sadanori Furudate; Takanori Hidaka; Setsuya Aiba
Journal:  Oncotarget       Date:  2018-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.